Urology · Lafayette, LA
NPI
1912093709
Since 2006
Specialty
Urology
Code 208800000X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
120 Rue Louis Xiv, Bldg 2
Lafayette, LA, 70508
Phone (337) 233-6665
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.0M
48,430 services
Medicare patients, 2024
1,218
Average age 75
Drug cost, 2024
$5.3M
4,995 prescriptions
Company payments, 2025
$1,320
From 16 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Thad A Bourque was code J1071 (injection, testosterone cypionate, 1 mg), 32,050 times for 15 patients. In total Thad A Bourque billed 48,430 services in 139 codes, and Medicare paid $1.0M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-04-15.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1071 Injection, testosterone cypionate, 1 mg | Office | 32,050 | 15 | $0.02 | $595 |
| J0585 Injection, onabotulinumtoxina, 1 unit | Office | 1,700 | 14 | $4.99 | $8,476 |
| 99214 Office E&M - Established | Office | 1,440 | 945 | $90.99 | $131K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 1,023 | 735 | $12.55 | $13K |
| J1952 Leuprolide injectable, camcevi, 1 mg | Office | 924 | 16 | $45.66 | $42K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 796 | 118 | $45.88 | $37K |
| 36415 Venipuncture Blood Collection | Office | 733 | 498 | $8.65 | $6,340 |
| 81003 Clinical Chemistry | Office | 681 | 461 | $2.20 | $1,498 |
| 84153 Clinical Chemistry | Office | 620 | 469 | $17.97 | $11K |
| 81001 Clinical Chemistry | Office | 492 | 304 | $3.09 | $1,520 |
| J0696 Injection, ceftriaxone sodium, per 250 mg | Office | 472 | 110 | $0.35 | $167 |
| 96372 Injection Administration | Office | 305 | 127 | $10.60 | $3,232 |
| 84403 Clinical Chemistry | Office | 248 | 191 | $25.21 | $6,252 |
| 51798 Ultrasound - Nonspecific | Office | 226 | 188 | $7.64 | $1,728 |
| 87084 Bacterial Culture | Office | 223 | 147 | $26.42 | $5,892 |
By year: 2022 $756K for 44,036 services; 2023 $1.3M for 54,452 services; 2024 $1.0M for 48,430 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 733 | 498 | $8.65 | $6,340 |
| 81003 Clinical Chemistry | 681 | 461 | $2.20 | $1,498 |
| 84153 Clinical Chemistry | 620 | 469 | $17.97 | $11K |
| 81001 Clinical Chemistry | 492 | 304 | $3.09 | $1,520 |
| 84403 Clinical Chemistry | 248 | 191 | $25.21 | $6,252 |
| 87084 Bacterial Culture | 223 | 147 | $26.42 | $5,892 |
| 80053 Clinical Chemistry | 216 | 118 | $10.31 | $2,228 |
| 85027 Blood Count | 152 | 107 | $6.31 | $959 |
| 87184 General Laboratory | 116 | 76 | $7.33 | $850 |
| 80048 Clinical Chemistry | 40 | 34 | $8.29 | $332 |
Medicare prescription drug claims, 2024
In 2024, the drug Thad A Bourque prescribed most often to Medicare patients was Tamsulosin Hcl, with 1,017 prescriptions and refills. In total Thad A Bourque wrote 4,995 Medicare prescriptions that cost $5.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tamsulosin Hcl Generic | 1,017 | 1,992 | 237 | $12K |
| Abiraterone Acetate Generic | 897 | 905 | 149 | $1.8M |
| Prednisone Generic | 861 | 975 | 141 | $2,792 |
| Finasteride Generic | 403 | 975 | 104 | $6,255 |
| Oxybutynin Chloride Er Oxybutynin Chloride | 293 | 460 | 84 | $6,364 |
| Gemtesa Vibegron | 137 | 165 | 28 | $75K |
| Myrbetriq Mirabegron | 127 | 169 | 25 | $75K |
| Nubeqa Darolutamide | 116 | 116 | 22 | $1.5M |
| Cefuroxime Cefuroxime Axetil | 100 | 111 | 76 | $1,664 |
| Xtandi Enzalutamide | 94 | 94 | 12 | $1.2M |
| Orgovyx Relugolix | 91 | 91 | 29 | $230K |
| Ciprofloxacin Hcl Generic | 77 | 77 | 62 | $489 |
| Testosterone Cypionate Generic | 70 | 75 | 14 | $1,316 |
| Methenamine Hippurate Generic | 63 | 84 | 12 | $3,360 |
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | 59 | 85 | 27 | $2,041 |
Brand drugs: 623 claims; generic drugs: 4,372 claims; opioid claims: 62.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Thad A Bourque $1,320 ($1,320 in general payments such as food, travel and fees) from 16 companies. The largest payer was Bioprotect Medical, Inc. with $198.
| Company | Payments | Amount |
|---|---|---|
| Bioprotect Medical, Inc. | 4 | $198 |
| Janssen Biotech, Inc. JNJ | 6 | $191 |
| Ferring Pharmaceuticals Inc. | 2 | $165 |
| Sumitomo Pharma America, Inc. 4506.T | 8 | $151 |
| Abbvie Inc. ABBV | 6 | $125 |
| Dendreon Pharmaceuticals LLC | 6 | $120 |
| Pfizer Inc. PFE | 5 | $80.81 |
| Merck Sharp & Dohme LLC MRK | 4 | $66.62 |
| Ethicon US, LLC JNJ | 2 | $56.56 |
| Laborie Medical Technologies Corp. | 1 | $53 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.